Wacker is investing in its production facilities for biologics, LMPs (live microbial products) and vaccines at its Amsterdam site. Projects include the construction of a new fermentation line with a volume of 1,500 liters as well as the setting up of new cleanroom structures in the 270-liter fermentation line. According to the company, the investment price is a mid-double-digit million-euro amount. Among other improvements, new utility supplies are planned, such as water for injection. These measures will contribute to preparing the plant to produce new classes of actives, such as pDNA and mRNA-based vaccines. Learn More